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Context: Germline mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene 
are responsible for a subset of familial isolated pituitary adenoma (FIPA) cases and sporadic 
pituitary neuroendocrine tumors (PitNETs).
Objective: To compare prospectively diagnosed AIP mutation-positive (AIPmut) PitNET patients 
with clinically presenting patients and to compare the clinical characteristics of AIPmut and 
AIPneg PitNET patients.
Design: 12-year prospective, observational study.
Participants & Setting: We studied probands and family members of FIPA kindreds and sporadic 
patients with disease onset ≤18 years or macroadenomas with onset ≤30 years (n = 1477). This 
was a collaborative study conducted at referral centers for pituitary diseases.
Interventions & Outcome: AIP testing and clinical screening for pituitary disease. Comparison of 
characteristics of prospectively diagnosed (n = 22) vs clinically presenting AIPmut PitNET patients 
(n = 145), and AIPmut (n = 167) vs AIPneg PitNET patients (n = 1310).
Results: Prospectively diagnosed AIPmut PitNET patients had smaller lesions with less suprasellar 
extension or cavernous sinus invasion and required fewer treatments with fewer operations 
and no radiotherapy compared with clinically presenting cases; there were fewer cases with 
active disease and hypopituitarism at last follow-up. When comparing AIPmut and AIPneg cases, 
AIPmut patients were more often males, younger, more often had GH excess, pituitary apoplexy, 
suprasellar extension, and more patients required multimodal therapy, including radiotherapy. 
AIPmut patients (n = 136) with GH excess were taller than AIPneg counterparts (n = 650).
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Conclusions: Prospectively diagnosed AIPmut patients show better outcomes than clinically 
presenting cases, demonstrating the beneits of genetic and clinical screening. AIP-related 
pituitary disease has a wide spectrum ranging from aggressively growing lesions to stable or 
indolent disease course. (J Clin Endocrinol Metab 105: 1–14, 2020)
Key Words:  pituitary neuroendocrine tumor, pituitary adenoma, familial isolated pituitary 
adenoma, somatotropinoma, gigantism, aryl hydrocarbon receptor-interacting protein
P
ituitary neuroendocrine tumors (PitNETs) are rela-
tively common (~1:1000 clinically relevant cases 
in the general population) and familial cases repre-
sent around 5% of this patient cohort (1,2). Familial 
isolated pituitary adenoma (FIPA) is a heterogeneous 
condition that involves the presence of PitNETs in 2 
or more members of the same family without other 
syndromic manifestations. Up to 20% of all FIPA and 
50% of familial acromegaly kindreds carry germline 
mutations in the aryl hydrocarbon receptor-interacting 
protein (AIP) gene (1,3,4). These mutations are also 
seen in sporadically diagnosed PitNETs (simplex 
cases), particularly in young patients, where the lack of 
family history is usually due to incomplete penetrance 
rather than de novo mutations (5–8). The typical AIP 
mutation-positive (AIPmut) phenotype is character-
ized by a young patient presenting with a large invasive 
growth hormone (GH)-secreting PitNET that is refrac-
tory to conventional treatments (1,3–5,9–11), with 
AIPmut somatotropinomas being responsible for 29% 
of pituitary gigantism cases (12).
Family members at risk of inheriting an AIP mu-
tation are recommended to undergo genetic testing 
and carriers are referred for clinical screening of pi-
tuitary disease (1,3,13–15). The rationale behind this 
strategy is that identifying PitNETs in AIPmut carriers 
with otherwise unrecognized disease at an early stage 
increases the likelihood of effective treatment and re-
mission (1,3,14). The assumption is that screening-
discovered PitNETs (ie, prospectively diagnosed 
PitNETs) are diagnosed at a less advanced stage and 
are less invasive than PitNETs with a clinical presenta-
tion, and thus should show a more favorable response 
to treatment and better clinical outcomes. However, 
these predicted advantages have never been actually 
shown in a prospective study.
Here, we present the results of a 12-year follow-up 
study on a large cohort of AIPmut patients, where we 
have characterized prospectively diagnosed AIPmut 
PitNET patients compared with clinically presenting 
cases. Our results highlight the critical importance 
of AIPmut genetic screening in selected individuals, 
and of clinical follow-up in known AIPmut carriers. 
Furthermore, we have expanded the description of 
AIPmut PitNET phenotype, disease course, and out-
comes compared with AIPneg cases.
Materials and Methods
Study population
We selected our study population from our cohort (2079 
patients with PitNETs and their 1029 unaffected relatives) 
recruited via the collaborative research network of the 
International FIPA Consortium (collaborators listed at the end 
of the manuscript) between February 2007 and April 2019; 
details of recruitment have been previously described (3). All 
participants gave written informed consent approved by the 
local ethics committee. Indications for AIP genetic testing 
were (1) patients with FIPA; (2) macroadenomas with disease 
onset at ≤30  years; and (3) PitNETs with disease onset at 
≤18 years. First-degree family members of individuals carrying 
AIP mutations were offered genetic testing. We included in 
our analysis all patients with known AIP mutational status 
matching these criteria (n = 1477). We excluded patients with 
undetermined affected status (ie, proven AIPmut carriers who 
did not undergo clinical screening or had pending clinical test 
results by the time of data analysis). Patients with X-linked 
acrogigantism or syndromic disease (multiple endocrine 
neoplasia type 1 (MEN1), MEN4, Carney complex, SDHx-
related, McCune–Albright and DICER1 syndromes, identiied 
on the basis of clinical, biochemical, and genetic testing as ap-
propriate) were excluded.
Of 1477 patients included in the study, 167 were AIPmut 
(33 not reported previously (11)), 154 with documented 
germline AIP pathogenic/likely pathogenic variant, and 13 af-
fected subjects with predicted AIPmut status (obligate carriers in 
AIPmut kindreds but not formally tested, including subjects al-
ready deceased). Pathogenicity of AIP variants was determined as 
previously described (3,11); only pathogenic or likely pathogenic 
variants were considered to be “mutations”. The AIPneg sub-
group included 1310 patients with PitNETs in whom a germline 
AIP mutation was excluded by genetic testing of all simplex 
probands and of the youngest affected member in the families.
Genetic testing and clinical screening
AIP testing was performed using either Sanger sequencing 
and multiplex ligation-dependent probe ampliication, or tar-
geted next-generation sequencing on genomic DNA obtained 
from blood or saliva samples (3,11,16). All the unaffected in-
dividuals with positive genetic screening for AIP were advised 
to undergo clinical, biochemical, and image screening tests by 
their local physician for the early diagnosis of possible pitu-
itary disease. Follow-up was advised on an annual basis or as 
appropriate (1,3,13).
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Study groups and clinical parameters
The familial cohort comprised patients with FIPA. The 
sporadic cohort included patients with young onset PitNETs 
(≤30 years) with no known family history of PitNETs or syn-
dromic disease. The clinical diagnoses were established as 
GH excess (acromegaly and gigantism), prolactinomas, clin-
ically nonfunctioning (NF)-PitNETs, Cushing’s disease, and 
thyrotropinomas, as previously described (3). Cases where the 
diagnosis was not speciied due to unavailability of histopatho-
logical, clinical, or biochemical data were termed “PitNET not 
speciied (NS)”. Age of onset was deined as the age of pres-
entation of irst symptoms. Macroadenomas were deined as 
tumor size ≥10 mm. Hypopituitarism at diagnosis and at last 
follow-up was deined as the presence of at least 1 pituitary de-
iciency documented biochemically. The number of treatments 
included the number of individual treatments received (each 
medication, surgery, and radiotherapy). Multimodal treatment 
was deined as the employment of 2 or more distinct forms of 
treatment in patient management. The reoperation subgroup 
involved patients who had at least 1 additional surgery fol-
lowing their irst operation. Active disease was considered in 
patients with secretory PitNETs displaying the respective pi-
tuitary hormone above the normal assay range, and/or evi-
dence of persistent or recurrent progressive tumor remnants in 
the surveillance pituitary magnetic resonance imaging (MRI) 
scans for both secretory PitNETs and NF-PitNETs. Small per-
sistent tumor remnants after operation, stable over a period of 
time, and requiring no further intervention were considered as 
not active NF-PitNETs.
Statistical analysis
Qualitative variables were expressed as percentages and 
analyzed with the χ 2 test to compare 2 or more groups. 
Quantitative or continuous variables were tested for Gaussian 
distribution with the Shapiro–Wilk test, and nonparametric 
and parametric data were then further analyzed with the 
Mann–Whitney U and Student t-tests, respectively. P < .05 was 
considered statistically signiicant. Statistical analyses were 
carried out using the SPSS software version 20 (IBM, USA) 
and GraphPad version 6 (Prism, USA). Data are presented as 
mean and standard deviation for continuous variables and as 
percentages for categorical variables.
Results
General characterization of the study 
population
Of the 1477 patients with PitNETs, 167 were AIPmut 
(11.3%), and 1310 were AIPneg patients (FIPA or age 
≤30  years at onset). Demographic and clinical char-
acteristics and comparative analysis of AIPmut vs 
AIPneg PitNETs are presented in Table  1 and Fig.  1. 
The familial cohort (355 families, 700 patients, 47% 
of the whole study population) consisted of 37 AIPmut 
kindreds (114 patients) and 318 AIPneg families (586 
patients). Of the 37 AIPmut families, 36 (97.8%) had 
at least 1 somatotropinoma case, 19 were homogeneous 
somatotropinoma kindreds, and 1 was homogeneous 
prolactinoma family. Of the 318 AIPneg families, 146 
(46%) were homogeneous and 172 were heterogeneous, 
with detailed subtypes shown in Table  2. In the spor-
adic cohort (n = 777), 53 (6.8%) had an AIP mutation 
(Table 1). Within the sporadic tumor subgroup, 10.5% 
(50 out of 477) of somatotropinomas, 1.5% (3 out of 
197)  of prolactinomas, and none (0 out of 54)  of the 
NF-PitNET cases were found to harbor a germline AIP 
mutation (Table 3; all supplementary material and ig-
ures are located in a digital research materials repository 
(17)).
Prospectively diagnosed vs clinically presenting 
AIPmut PitNETs
Genetic testing of AIPmut kindreds identiied 187 ap-
parently unaffected AIPmut carriers. A total 165 AIPmut 
carriers were disease free at both baseline screening and 
at last follow-up assessment (mean follow-up duration 
5.9 ± 3.3 years, ranging between 1 and 11 years), while 
22 subjects (11.8%) were prospectively diagnosed with 
a PitNET. The mean age at diagnosis of prospectively 
diagnosed AIPmut PitNET patients (30.4 ± 15.7 years) 
and the age at genetic testing of unaffected AIPmut car-
riers (35.9 ± 24.1 years) did not differ (P = .453). There 
was no signiicant difference in the gender distribution 
either: 49.7% prospectively diagnosed males vs 63.6% 
unaffected carrier males (P = .219).
Three of these prospectively diagnosed cases had 
normal biochemistry and contrast-enhanced pitu-
itary MRI scan at baseline screening, but went on to 
develop a PitNET during the subsequent follow-up: 2 
small NF-PitNETs and 1 microprolactinoma, being 
stable since their initial detection and none requiring 
intervention to date. Eight of the 22 cases (36%) had 
retrospectively recognized symptoms that could be 
attributed to pituitary disease. Prospectively diag-
nosed PitNETs were smaller than clinically presenting 
tumors (10 ± 7 vs 24 ± 13 mm; P  <  .001), and 68% 
vs 8% were microadenomas (P  <  .001, Table  4 and 
Fig.  2A). Prospectively diagnosed PitNETs were asso-
ciated with lower rates of hypopituitarism at diagnosis 
(0 vs 58%; P < 0.001), suprasellar extension (11% vs 
68%; P  <  .001), and cavernous sinus invasion (11% 
vs 44%; P = .010) (Table 4 and Fig. 2A). Prospectively 
diagnosed cases required fewer treatments (0.7  ±  1.0 
vs 2.3  ±  1.7; P  <  .001) and operations (0.4  ±  0.5 vs 
1.0  ±  0.8; P  <  .001), none received radiotherapy (vs 
38%; P  <  .001), and had decreased rates of active 
disease (6% vs 28%; P = .039) and hypopituitarism (0 
vs 41%; P = .003) at last follow-up (Table 4 and Fig. 2B 
and 2C).
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Prospectively diagnosed somatotropinomas, NF-PitNETs 
and prolactinomas had signiicantly lower rates of hypo-
pituitarism at diagnosis, macroadenomas, and suprasellar 
extension, requiring fewer treatments than those clinic-
ally presenting counterparts (Table 4). Prospectively diag-
nosed AIPmut somatotropinomas were also signiicantly 
smaller and none required radiotherapy (P = .009). None 
of the prospectively diagnosed AIPmut NF-PitNETs had 
hypopituitarism (P =  .002) or active disease (P =  .035) 
at last follow-up (Table  4). Two AIPmut patients had 
prospectively diagnosed microprolactinomas with no 
suprasellar extension or cavernous sinus invasion, and 
were eupituitary at diagnosis and at last follow-up: 1 re-
sponded well to dopamine agonist and the other is under 
observation (described in detail as case 5 in (14)).
AIP mutations in the study population
Forty-four different germline pathogenic/likely patho-
genic AIP mutations were identiied, including 5 previ-
ously not described mutations (exon 1 deletion; c.344delT 
(p.L115fs*41); c.773T>G (p.L258R); c.779delA 
(p.K260fs*44); c.863_864del (p.F288Cfs*?)), among the 
167 AIPmut patients (17). The most common mutation 
types were nonsense mutations (27%) and frameshift mu-
tations (25%), followed by missense (18%), splice site 
(7%), in-frame insertions/deletions (9%), and large gen-
omic deletions (7%), and we had 1 each of promoter, start 
site, and stop-loss mutations. Of 167 AIPmut PitNETs, 
127 (76%) were due to a truncating mutation, and the 
most frequent AIP mutation was c.910C>T (p.R304*), 
which was detected in 57 patients.
In our study population, we identiied 17 different AIP 
variants classiied as benign, likely benign, or variants of 
uncertain signiicance according to the American College 
of Medical Genetics and Genomics and the Association 
for Molecular Pathology criteria (17,18). We note 
that one of the most common AIP variants identiied, 
p.R304Q, although controversial, is currently classiied 
as variant of uncertain signiicance (19), patients from 
these kindreds were allocated to the AIPneg subgroup.
Table 1. Characteristics of the study population and comparative analysis of AIPmut vs AIPneg patients 
AIPmut vs AIPneg PitNETs
Overall study  
population  
n = 1477
AIPmut AIPneg
Pn = 167 n = 1310
Cohort type based on family history of PitNETs     
 Familial cohort 68.3 44.7 <.001 47.4
 Sporadic cohort 31.7 55.3  52.6
Gender     
 Male 61.1 45.2 <.001 47.0
 Female 38.9 54.8  53.0
Age at disease onset ≤18 yr 64.8 28.8 <.001 33.1
Age at irst symptoms (yr) 19.0 ± 9.5 26.8 ± 13.1 <.001 25.9 ± 13.0
Age at diagnosis (yr) 24.3 ± 11.9 30.0 ± 13.5 <.001 29.4 ± 13.5
Delay in diagnosis (yr) 4.1 ± 6.6 3.2 ± 4.9 .212 3.3 ± 5.1
GH excess 81.4 49.6 <.001 53.2
Pituitary apoplexy 8.2 3.6 .009 4.2
Hypopituitarism at diagnosis 42.7 49.0 .318 47.9
Number of pituitary deiciencies at diagnosis 0.84 ± 1.11 0.79 ± 1.03 .841 0.80 ± 1.05
Macroadenoma 83.2 79.2 .259 79.7
Maximum tumor diameter (mm) 20.1 ± 13.0 22.8 ± 16.0 .281 22.5 ± 15.7
Suprasellar extension 54.3 42.4 .043 43.9
Cavernous sinus invasion 36.7 28.3 .122 29.3
Ki-67 > 3% 41.4 41.0 .972 41.1
Number of treatments 2.07 ± 1.66 1.87 ± 1.32 .228 1.90 ± 1.38
Number of surgeries 0.93 ± 0.79 0.87 ± 0.72 .468 0.88 ± 0.73
Reoperation 23.1 16.9 .106 17.8
Radiotherapy 32.9 21.5 .002 23.2
Multimodal treatment 67.2 47.0 <.001 49.7
≥3 treatments 40.3 25.8 <.001 27.7
Active disease at last follow-up 25.0 34.5 .041 32.8
Hypopituitarism at last follow-up 29.6 33.6 .574 32.9
Number of pituitary deiciencies at last follow-up 0.45 ± 0.96 0.77 ± 1.27 .148 0.71 ± 1.22
Follow-up duration (yr) 11.2 ± 12.3 7.8 ± 9.5 .008 8.4 ± 10.1
Categorical data are shown as %; continuous variables are shown as mean ± standard deviation. P values in bold are those < .05 (statistically 
signiicant).
Abbreviations: AIPmut, AIP mutation-positive; AIPneg, AIP mutation-negative; GH, growth hormone; PitNET, pituitary neuroendocrine tumor; yr, 
years.
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Comparative analysis of AIPmut vs AIPneg 
patients
Overall, patients with AIPmut were more frequently 
males (61% vs 45%; P  <  .001) than AIPneg  pa-
tients, 8 years younger at irst symptoms, and 6 years 
younger at diagnosis, with disease onset ≤18 years in 
65% and <30  years in 87% (Table  1 and Fig.  1A). 
AIPmut PitNETs had a higher rate of pituitary apo-
plexy and suprasellar extension, more often required 
radiotherapy, and multimodal and multiple treatments 
than AIPneg ones (Table 1). Patients with AIPmut had 
lower rates of active disease at last follow-up (25% 
vs 35%; P = .041). However, as AIPmut had a longer 
follow-up, we analyzed only patients with no longer 
than a 10 year follow-up, and then there was no differ-
ence in the rate of active disease at last follow-up (39% 
vs 43%; P = .642).
AIPmut PitNETs were more often associated with 
GH excess, with gigantism being the predominant clin-
ical diagnosis (Fig. 1B and (17)). AIPmut patients with 
GH excess were younger than AIPneg cases (Table 3). 
There was no difference in insulin-like growth factor 1 
(IGF-1) levels at diagnosis between patients presenting 
clinically with AIPmut and AIPneg (P = .696, Table 3). 
All AIPmut somatotropinomas were sparsely granulated 
in contrast to 68% of the AIPneg ones (P < .001); similar 
ratios were seen considering only AIPmut and AIPneg 
giants. AIPmut somatotropinomas were associated with 
higher rates of pituitary apoplexy, suprasellar extension, 
radiotherapy, and reoperation, and showed trends for 
an increased need for multimodal therapy (P  =  .076) 
and ≥3 treatments (P = .079). The mean inal height was 
higher in the AIPmut somatotropinoma subgroup both 
for males (193 ± 18 vs 185 ± 14 cm; P = .004) and fe-
males (175 ± 13 vs 169 ± 9  cm; P  =  .017) (Table 3). 
Patients with AIPmut prolactinomas had higher rates 
of pituitary apoplexy than AIPneg counterparts, which 
remained signiicantly higher when considering only 
clinically presenting cases (17). AIPmut NF-PitNETs 
had lower rates of macroadenomas, hypopituitarism at 
last follow-up, lower tumor diameter, and fewer pitu-
itary deiciencies at diagnosis, as well as requiring fewer 
treatments and surgery than their nonmutated counter-
parts; however, when excluding the 10 prospectively 
diagnosed AIPmut NF-PitNETs patients these signii-
cant differences were lost ((17)).
Figure 1. Distribution of AIPmut vs AIPneg PitNETs according to age at onset (A) and to clinical diagnosis (B). Numbers above columns represent 
percentage of patients. We note that the two AIPmut cases with irst symptoms in the 5th and 6th decade, both had macroprolactinomas, 1 
presenting with apoplexy. ACTHoma, ACTH-secreting adenoma or Cushing’s disease; AIPmut, AIP mutation-positive; AIPneg, AIP mutation-
negative; PitNET NS, pituitary neuroendocrine tumor not speciied; NF-PitNET, non-functioning PitNET; PRLoma, prolactinoma; TSHoma, 
thyrotropinoma; yr, years.
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Discussion
We assessed the clinical value of genetic testing for AIP 
mutations with subsequent clinical screening of carriers 
in a cohort of patients with familial and young-onset 
PitNETs. In addition, we have compared the clinical 
features between AIPmut and AIPneg patients. Our 
key focus was on the follow-up of carriers and on pro-
spectively diagnosed AIPmut patients, as the clinical 
and therapeutic characterization of this subgroup is 
lacking. The clinical screening of carrier family mem-
bers of AIPmut probands has been recommended on the 
assumption that the early detection of PitNETs might be 
associated with more favorable outcomes (1,3,13,14); 
however, these predicted advantages had not been pre-
viously demonstrated in a prospective study.
In the current study, among the 187 apparently un-
affected AIPmut carriers, 22 were identiied with a pro-
spectively diagnosed PitNET by clinical, biochemical, and 
imaging screening. As a group, prospectively diagnosed 
AIPmut PitNETs were mainly microadenomas, smaller, 
and were associated with lower rates of suprasellar ex-
tension, cavernous sinus invasion, and hypopituitarism 
at diagnosis, and required fewer treatments, operations, 
no radiotherapy, and had reduced rates of active disease 
and hypopituitarism at last follow-up when compared 
with their clinically presenting counterparts. Similar 
results were obtained when prospectively diagnosed 
AIPmut somatotropinomas and AIPmut NF-PitNETs 
were analyzed separately. Overall, prospectively diag-
nosed AIPmut PitNETs are signiicantly less invasive and 
associated with better outcomes than those with a clin-
ical presentation, highlighting the beneits of AIP gen-
etic testing of family members at risk and the screening 
of individuals carrying an AIP mutation (1,11,13,20).
In our series, 3 prospectively diagnosed PitNETs were 
not present at baseline assessment, but emerged during 
the follow-up (5–7  years after the initial screening), 
reinforcing the need for surveillance of unaffected 
AIPmut carriers (1,3,13,14). These 3 cases are currently 
under observation, requiring no treatment. The AIPmut 
nonfunctioning microadenomas we have identiied in 
our study are somewhat similar to the screening-detected 
MEN1-related pituitary tumors described elsewhere 
(21). In a different study, Tichomirowa et al. identiied 
2 patients with PitNETs among the 21 AIPmut carriers 
screened (9.5%), both clinically silent microadenomas 
requiring no intervention (8). Both AIPmut and MEN1-
related prospectively diagnosed PitNETs should be 
managed in accordance with current guidelines (21–27).
There are 4 key questions for clinicians managing pa-
tients with PitNET regarding AIP: (1) Which clinically 
presenting pituitary tumor patients should be tested for 
AIP mutations? (ii) How to manage clinically presenting 
Table 2. AIPmut and AIPneg FIPA kindreds according to pituitary tumor types 
PitNET types within the same kindred
AIPmut kindreds AIPneg kindreds Total
n = 37 n = 318 n = 355
ACTHoma only 0 7 (2.2) 7 (2.0)
ACTHoma + FSHoma 0 1 (0.3) 1 (0.3)
ACTHoma + GHoma 0 7 (2.2) 7 (2.0)
ACTHoma + NF-PitNET 0 1 (0.3) 1 (0.3)
ACTHoma + NF-PitNET + PitNET NS 0 1 (0.3) 1 (0.3)
ACTHoma + NF-PitNET + PRLoma 0 1 (0.3) 1 (0.3)
ACTHoma + PitNET NS 0 2 (0.6) 2 (0.6)
ACTHoma + PRLoma 0 8 (2.5) 8 (2.3)
GHoma only 19 (51.4) 68 (21.4) 87 (24.5)
GHoma + NF-PitNET 8 (21.6) 25 (7.9) 33 (9.3)
GHoma + NF-PitNET + PRLoma 1 (2.7) 4 (1.3) 5 (1.4)
GHoma + PitNET NS 0 19 (6.0) 19 (5.3)
GHoma + PitNET NS + PRLoma 0 1 (0.3) 1 (0.3)
GHoma + PRLoma 8 (21.6) 45 (14.2) 53 (14.9)
NF-PitNET only 0 24 (7.5) 24 (6.8)
NF-PitNET + PitNET NS 0 14 (4.4) 14 (3.9)
NF-PitNET + PRLoma 0 24 (7.5) 24 (6.8)
PRLoma only 1 (2.7) 47 (14.8) 48 (13.5)
PRLoma + FSHoma 0 1 (0.3) 1 (0.3)
PRLoma + PitNET NS 0 18 (5.7) 18 (5.1)
Data are shown as n (%).
Abbreviations: ACTHoma, ACTH-secreting adenoma or Cushing’s disease; AIPmut, AIP mutation-positive; AIPneg, AIP mutation-negative; FSHoma, 
FSH-secreting adenoma; GHoma, GH-secreting adenoma or somatotropinoma (this category includes acromegaly and gigantism cases); PitNET NS, 
pituitary neuroendocrine tumor not speciied; NF-PitNET, nonfunctioning PitNET; PRLoma, prolactinoma.
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AIPmut PitNET patients? (3) When to initiate genetic 
screening for family members of a proband? and (4) What 
should be the clinical follow-up of AIPmut carriers?
 1. Which clinically presenting pituitary tumor pa-
tient should be tested for AIP mutations? We 
have recently showed that based on 4 simple fac-
tors (age of onset, family history, tumor type, and 
tumor size), the risk of carrying an AIP mutation 
can be predicted (11). As mutation status correl-
ates with age of disease onset better than age of 
diagnosis (3), careful history taking is key. For ex-
ample, age at onset between 19 and 30 years is an 
independent risk factor for patients with sporadic 
Table 3. Comparative analysis between AIPmut vs AIPneg somatotropinomas
AIPmut vs AIPneg somatotropinomas
Overall somatotropinomas 
n = 786
AIPmut AIPneg
P n = 136 n = 650
Cohort type based on family history of PitNETs     
 Familial cohort 63.2 34.3 <.001 39.3
 Sporadic cohort 36.8 65.7  60.7
Gender     
 Male 61.8 51.3 .026 53.1
 Female 38.2 48.7  46.9
Age at disease onset ≤ 18 yr 67.5 25.0 <.001 32.7
Age at irst symptoms (yr) 18.1 ± 8.4 26.1 ± 11.8 <.001 24.7 ± 11.7
Age at diagnosis (yr) 23.2 ± 10.8 30.2 ± 12.2 <.001 28.9 ± 12.3
Delay in diagnosis (yr) 4.3 ± 6.5 4.2 ± 5.4 .371 4.2 ± 5.6
Gigantism 55.9 18.2 <.001 24.7
Pituitary apoplexy 8.3 2.8 .005 3.8
Height at diagnosis (cm)     
 Males 188.8 ± 19.7 183.5 ± 14.7 .054 184.8 ± 16.2
 Females 170.4 ± 11.2 168.9 ± 9.0 .392 169.3 ± 9.5
Height Z-score at diagnosis 2.7 ± 2.4 1.5 ± 1.9 <.001 1.8 ± 2.1
Insulin-like growth factor 1 × ULN at diagnosis 2.5 ± 3.5 2.9 ± 2.3 <.001 2.8 ± 2.5
2.7 ± 3.8 2.9 ± 2.3 .696 2.9 ± 2.5
Hypopituitarism at diagnosis 46.4 49.0 .742 48.3
Number of pituitary deiciencies at diagnosis 0.89 ± 1.12 0.71 ± 0.90 .565 0.76 ± 0.97
Macroadenoma 90.0 89.2 .796 89.3
Maximum tumor diameter (mm) 23.0 ± 11.9 24.8 ± 13.6 .403 24.5 ± 13.3
Suprasellar extension 60.3 46.2 .042 48.7
Cavernous sinus invasion 41.9 35.7 .356 36.8
Granulation pattern     
 Densely granulated 0 31.9 <.001 22.1
 Sparsely granulated 100 68.1  77.9
Ki-67 > 3% 44.0 35.7 .519 37.9
Number of treatments 2.35 ± 1.68 2.30 ± 1.41 .821 2.31 ± 1.47
Number of surgeries 1.06 ± 0.78 1.07 ± 0.61 .606 1.07 ± 0.65
Reoperation 25.2 16.1 .025 17.8
Radiotherapy 38.9 28.2 .018 30.5
Somatostatin analogues 45.4 54.2 .073 52.4
Dopamine agonists 23.8 26.3 .572 25.8
Pegvisomant 10.8 6.8 .127 7.6
Multimodal treatment 72.4 63.7 .076 65.4
≥3 treatments 45.7 36.9 .079 38.6
47.7 36.9 .039 39.0
Active disease at last follow-up 27.7 43.3 .005 39.6
Hypopituitarism at last follow-up 36.1 39.1 .752 38.3
Number of pituitary deiciencies at last follow-up 0.48 ± 0.93 0.79 ± 1.22 .288 0.71 ± 1.15
Final height (cm) 185.9 ± 18.3 177.9 ± 14.3 <.001 179.7 ± 15.6
Final height (cm) by gender     
 Males 192.8 ± 17.6 185.2 ± 13.8 .004 187.1 ± 15.1
 Females 174.8 ± 13.4 168.9 ± 8.7 .017 170.1 ± 10.0
Follow-up duration (yr) 11.4 ± 12.8 7.4 ± 8.9 .027 8.3 ± 10.0
Categorical data are shown as %; continuous variables are shown as mean ± standard deviation. Data for clinically presenting somatotropinomas 
comparison are added in italics where showing different results. Data for clinically presenting somatotropinomas comparison are added in italics 
where showing different results. P values in bold are those < .05 (statistically signiicant).
Abbreviations: AIPmut, AIP mutation-positive; AIPneg, AIP mutation-negative; PitNET, pituitary neuroendocrine tumor; ULN, upper limit of the 
normal; yr, years.
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Table 4. Comparative analysis between prospectively diagnosed vs clinically presenting AIPmut PitNETs 
AIPmut PitNETs AIPmut somatotropinomas AIPmut NF-PitNETs
Prospectively 
diagnosed
Clinically 
presenting
P 
Prospectively 
diagnosed
Clinically 
presenting
P value
Prospectively-
diagnosed
Clinically-
presenting
P valuen = 22 n = 145 n = 10 n = 126 n = 10 n = 4
Gender          
 Male 63.6 60.7 .792 70.0 61.1 .578 60.0 75.0 .597
 Female 36.4 39.3  30.0 38.9  40.0 25.0  
Age at diagnosis (yr) 30.4 ± 15.7 23.5 ± 11.1 .065 32.6 ± 15.7 22.4 ± 10.0 .022 29.9 ± 16.3 27.0 ± 11.5 1.000
Clinical diagnosis          
 Acromegaly 36.4 35.9 <.001       
 Gigantism 9.1 51.0        
 Prolactinoma 9.1 10.3        
 NF-PitNET 45.4 2.8        
GH excess 45.5 86.9 <.001       
Hypopituitarism at diagnosis 0 58.2 <.001 0 54.2 .004 0 100 .001
Number of pituitary deiciencies 
at diagnosis
0 1.15 ± 1.19 <.001 0 1.04 ± 1.15 .008 0 2.00 ± 0 .002
Macroadenoma 31.8 92.1 <.001 60.0 92.7 .001 10.0 100 .003
Maximum tumor diameter (mm) 9.5 ± 7.2 23.8 ± 12.6 <.001 14.1 ± 7.6 24.5 ± 11.9 .015 6.4 ± 5.0 35.0 .113
Suprasellar extension 10.5 67.7 <.001 12.5 67.3 .003 11.1 100 .011
Cavernous sinus invasion 11.1 44.3 .010 14.3 45.5 .115 11.1 50.0 .197
Ki-67 > 3 16.7 47.8 .168 20.0 50.0 .227 0 50.0 .386
Number of treatments 0.68 ± 0.95 2.29 ± 1.65 <.001 1.20 ± 1.03 2.45 ± 1.69 .015 0.20 ± 6.32 1.33 ± 0.58 .010
Number of surgeries 0.36 ± 0.49 1.01 ± 0.79 <.001 0.70 ± 0.48 1.09 ± 0.79 .105 0.10 ± 0.32 1.00 ± 0 .004
Reoperation 0 24.8 .108 0 27.0 .112 0 0 1.000
Radiotherapy 0 38.1 <.001 0 42.1 .009 0 33.3 .057
Multimodal treatment 55.6 68.0 .443 57.1 73.4 .351 0 33.3 .248
≥ 3 treatments 11.1 42.4 .065 14.3 47.7 .085 0 0 1.000
Active disease at last follow-up 5.6 28.3 .039 11.1 29.3 .243 0 50.0 .035
Hypopituitarism at last follow-up 0 41.0 .003 0 40.6 .111 0 100 .002
Number of pituitary deiciencies 
at last follow-up
0 0.65 ± 1.10 .014 0 0.56 ± 0.97 .220 0 1.00 ± 0 .003
Follow-up duration (yr) 5.3 ± 4.5 12.4 ± 13.0 .067 5.5 ± 4.8 12.0 ± 13.2 .276 5.1 ± 4.7 19.5 ± 0.7 .030
Categorical data are shown as %; continuous variables are shown as mean ± standard deviation. P values in bold are those < .05 (statistically signiicant).
Abbreviations: AIPmut, AIP mutation-positive; NF-PitNET, non-functioning pituitary neuroendocrine tumor; yr, years.
Downloaded from https://academic.oup.com/jcem/article-abstract/105/6/dgaa040/5717684 by guest on 11 June 2020
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PitNET to carry an AIP mutation; however, pa-
tients in this age group without GH excess or an 
absence of family history have a lower risk (11). 
Hence, risk prediction should take several param-
eters into account, and for patients with fewer risk 
factors the age cut-off for AIP testing could be 
lower than 30 years (11,28). Our fact-inding study 
shows that many patients with sporadic PitNET 
who undergo AIP analysis based on age at onset 
≤30 years (3–5,11) will have negative results. In our 
young-onset sporadic PitNET cohort, 6.8% had 
an AIP mutation, with slightly higher rates in the 
sporadic somatotropinoma subgroup (10.5%); this 
is at the level of usual risk recommendation for gen-
etic testing, but we identiied low rates in sporadic 
prolactinomas (1.5%) with no cases of NF-PitNETs 
or corticotropinomas.
 2. How to manage clinically presenting AIPmut PitNET 
patients? This is an important question but is largely 
beyond the scope of this article. There are numerous 
factors which need to be taken into account due to 
young onset, often aggressively growing tumors, and 
treatment should follow current guidelines, with at-
tention to some characteristic features, such as ag-
gressive growth, recurrence, poor response to irst-
generation somatostatin analogues with, at least in 
some cases, better responses to second-generation 
somatostatin analogues (29), and the risk of apo-
plexy. On the other hand, some cases show slower 
growth or stable nonfunctioning microadenomas, as 
shown in our data here.
 3. When to initiate genetic screening for family mem-
bers of a proband? We suggest germline AIP mutation 
genetic testing be offered at the earliest opportunity 
Figure 2. Patient characteristics (A) and treatment modalities (B,C). Clinical variables (A) and treatment characteristics (B,C) in patients with a 
clinically presenting PitNET, with or without AIP mutation (AIPmut and AIPneg), and in AIPmut carriers with an abnormality identiied at clinical 
screening (prospectively diagnosed cases). (C) Data are shown as mean ± standard deviation.
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to irst-degree relatives including children, because 
the disease may manifest by the age of 4 years (30).
 4. What should be the clinical follow-up of AIPmut 
carriers? Our experience, based on this cohort, sug-
gests that careful baseline assessment of AIPmut car-
riers (including clinical examination, measurement of 
serum IGF-1 and prolactin, and pituitary MRI) picks 
up the largest number of pituitary abnormalities. 
As AIP mutation testing has only been established 
just over a decade ago, the age range of establishing 
carrier status was very wide in our cohort. How-
ever, as testing is now routinely available, we pre-
dict that a larger number of carriers will be followed 
starting at an early age. As the age of disease onset 
has an inverted U shape (Fig. 1A), the recommenda-
tion for carrier follow-up could be different for the 
various age groups. For AIPmut carriers until the age 
of 20  years, annual clinical assessment with meas-
urement of IGF-1 and prolactin and baseline MRI 
(starting at 10 years for younger carriers) followed 
by 5-yearly scans could be appropriate. Follow-up 
between 21 and 30 years, if assessment is normal at 
age 20  years, probably could be relaxed. Our data 
also raise the possibility that adult AIPmut carriers 
with a normal baseline assessment could be followed 
with clinical and biochemical assessment, with fur-
ther pituitary MRI only indicated in case of symp-
toms or biochemical abnormalities. Most clinically 
presenting cases show symptoms before the age of 
30 years (1,3), and we are not aware of any case with 
a normal full assessment at age ≥30 years who later 
developed a PitNET. However, a cost-effectiveness 
analysis evaluating the economic burden of genetic 
testing and clinical screening programs in this setting, 
while weighing the beneits of early detection of AIP-
related pituitary disease we show in this study, is cur-
rently lacking.
In the AIPmut and AIPneg comparison, AIPmut 
PitNETs presented earlier with more aggressive disease 
and were more dificult to treat, as seen in previous 
studies (3–5,10,31). Nevertheless, our data show that 
some AIPmut PitNETs will not display an aggressive 
phenotype (4,8,12,32). Interestingly, the inclusion of 
aggressive or therapy resistant pituitary disease did not 
increase the frequency of AIP mutations in a recent 
study (28). Moreover, in our cohort, the rate of active 
disease at last follow-up was 10% lower in the AIPmut 
PitNETs group, suggesting that AIPmut PitNETs can be 
satisfactorily controlled despite requiring more complex 
and multimodal therapeutic schemes (12,29,30,33,34). 
Although these data may seem paradoxical (more 
aggressive disease at presentation in the AIPmut pa-
tients, but better controlled disease at last follow-up), 
they could be explained by a more aggressive treat-
ment approach in AIPmut cases, especially the use of 
radiotherapy. Another possibility is that the follow-up 
of AIPneg cases in our cohort was somewhat shorter; 
indeed, considering a cut-off of a maximum of 10 years 
of follow-up, there was no difference in rate of active 
disease between the 2 groups. Rostomyan et  al. also 
reported higher rates of biochemical control at last 
follow-up and a trend for increased long-term controlled 
disease in patients with AIPmut pituitary gigantism in 
comparison to genetically negative gigantism cases (12). 
Thus, these data suggest that management of AIPmut 
patients can be challenging, but the disease is control-
lable in a signiicant proportion of cases.
Among AIPmut patients, somatotropinomas were the 
main PitNET subtype and gigantism the predominant 
clinical diagnosis, as previously shown (4, 11). IGF-1 
levels at diagnosis did not differ between clinically pre-
senting AIPmut and AIPneg somatotropinoma patients, 
suggesting that AIPmut somatotropinomas are not bio-
chemically more active at presentation than their AIPneg 
counterparts, similar to earlier data (4). AIPmut patients 
with gigantism also showed similar IGF-1 levels in our 
cohort (35), although AIPneg giants had higher IGF-1 in 
another cohort (12). AIPmut somatotropinoma patients 
received radiotherapy more frequently than AIPneg pa-
tients, for which a nonsigniicant trend had been observed 
previously (4). In addition, the mean inal height in our 
cohort was higher in the AIPmut somatotropinoma sub-
group, with both AIPmut males and females ending up 
taller than AIPneg counterparts, although this has not 
been consistently shown in other series (12). The taller 
inal height in our AIPmut somatotropinoma patients is 
likely due to earlier onset of disease, but it may also re-
lect the management dificulties.
We found no differences regarding treatment and clin-
ical outcomes in the comparative analysis of AIPmut vs 
AIPneg prolactinomas. Although numbers are small, this 
suggests that AIPmut prolactinomas may not be more 
refractory to medical therapy, in line with a previous re-
port showing that presence of an AIP mutation in chil-
dren or adolescents with macroprolactinomas does not 
inluence the response to dopamine agonists (32).
AIPmut NF-PitNETs were smaller, had less pituitary 
deiciencies at diagnosis, and required fewer treatments 
and operations than AIPneg NF-PitNETs; however, these 
differences were lost when the 10 prospectively diagnosed 
cases were excluded from the analysis. In fact, clinically 
presenting AIPmut NF-PitNETs were macroadenomas, 
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and had suprasellar extension and hypopituitarism at 
diagnosis/last follow-up, and half remain uncontrolled at 
last follow-up. Clinically presenting AIPmut NF-PitNETs 
reported previously were also noted for their aggressive 
behavior (4). Some of the small prospectively diagnosed 
AIPmut NF-PitNETs may represent incidentalomas similar 
to those often observed in the general population, al-
though incidentalomas are more common in older subjects 
(2,22). Prospectively diagnosed MEN1 mutation-positive 
NF-PitNETs also display an indolent behavior, do not pro-
gress to macroadenomas, and often require no interven-
tion (21,36). Overall, our data show that not all AIPmut 
PitNETs are aggressive or dificult to manage, as some 
patients have slowly growing or indolent NF-PitNETs 
(possibly representing incidentalomas) requiring no inter-
vention, suggesting that the spectrum of AIP-related pitu-
itary disease is wider than previously suggested.
Our study has some limitations: (1) we used the onset 
of symptoms age cut-off ≤30 years as a criterion to guide 
AIP genetic testing in patients with young-onset sporadic 
PitNETs, as in previous AIP-related studies (3–5,11). 
This age cut-off relies on age of onset, which can be sub-
jective; however, age of onset rather than age at diag-
nosis is suggested to be a better option to guide genetic 
testing as PitNETs are often diagnosed with signiicant 
delay (11); (2) our patients were recruited from several 
countries and thus their clinical features and outcomes 
may be affected by their different genetic backgrounds 
and/or different local clinical practices; (3) we assigned, 
based on current experimental, clinical and in silico 
data, the AIP variants into pathogenic/likely pathogenic, 
or variant of uncertain signiicance/likely benign/benign 
groups; however, these categories may change as these 
variants are better characterized; (4) since the apparently 
unaffected participants of our study were genetically and 
clinically screened at various ages, we cannot determine, 
at this point, the disease penetrance for the prospectively 
diagnosed cohort per age group.
Conclusions
Genetic testing followed by clinical screening in AIPmut 
kindreds can detect clinically relevant pituitary disease, 
where earlier intervention results in better outcomes. 
While clinically presenting AIPmut PitNETs occur in 
younger patients with more advanced disease, complex 
treatment strategies can result in well-controlled disease. 
There is a wider spectrum of disease severity in AIPmut 
PitNET patients, even within the same family, than pre-
viously suspected. When considering patients for AIP 
mutation testing, key clinical factors help to predict the 
risk level to guide decision making.
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